Jianfeng Group Lin2017 -019 (Announcement on Related Party Transactions of Equity Reorganization in Shanya South)
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2017-019
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于山亚南方股权重组的关联交易公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l 与同一关联人已经发生的关联交易情况:今年以来,本公司累计向本次交易对方南方尖峰的同一关联人浙江虎鹰水泥有限公司、广西虎鹰水泥有限公司分别收取商标使用费(不含税金额)93.95万元、230.21万元,合计324.16万元。
一、关联交易基本情况
(一)本次股权重组的基本情况
本公司控股子公司浙江尖峰水泥有限公司(以下简称“尖峰水泥”)持有浙江金华南方尖峰水泥有限公司(以下简称“南方尖峰”)35%股权,金华南方水泥有限公司(以下简称“金华南方”)持有南方尖峰65%股权;南方尖峰持有杭州山亚南方水泥有限公司(以下简称“山亚南方”)的100%股权。
为了压减企业层级、提高运营效率,拟对山亚南方进行股权重组,将南方尖峰持有的山亚南方100%股权转让给尖峰水泥与金华南方两个股东,尖峰水泥与金华南方按所占南方尖峰的股权比例受让山亚南方股权,其中:尖峰水泥拟出资62,099,765元受让山亚南方的35%股权;金华南方拟出资115,328,135元受让山亚南方的65%股权。
另,尖峰水泥和金华南方还拟对南方尖峰进行减资。
(二)关联关系
本公司董事长蒋晓萌先生兼任南方尖峰、金华南方法定代表人,按照《上海证券交易所股票上市规则》有关规定,南方尖峰、金华南方为本公司关联法人,本次收购股权行为构成关联交易。
(三)本次关联交易金额为62,099,765元,占本公司2016年经审计归属于母公司净资产的2.6%(未超过5%)。根据公司《章程》的规定,本次关联交易需经董事会审议,无需提交股东大会审议。关联董事蒋晓萌先生需回避本议案的表决。本次关联交易事项不构成《上市公司重大资产重组管理办法》规定的重大资产重组。
二、关联方介绍
(一)南方尖峰基本情况
1、名称:浙江金华南方尖峰水泥有限公司
2、企业性质:有限责任公司
3、注册地:浙江省金华市婺城区婺江东路88号
4、主要办公地点:浙江省金华市婺城区婺江东路88号
5、法定代表人:蒋晓萌
6、注册资本:人民币4亿元
7、经营范围:水泥、水泥制品生产、研发及销售(水泥、水泥制品生产的分支机构经营场所设在金华市婺城区竹马乡济台寺金马水泥厂内)。
8、目前的股权结构:
|
股东名称 |
占注册资本的比例(%) |
|
金华南方水泥有限公司 |
65 |
|
浙江尖峰水泥有限公司 |
35 |
9、南方尖峰最近一年的主要财务指标
经具有从事证券、期货业务资格的天职国际会计师事务所审计(天职业字[2017]9406号),截止2016年12月31日,南方尖峰的合并报表总资产为98286.15万元,归属于母公司所有者权益73571.26万元;2016年的营业总收入为59340.55万元,归属于母公司所有者的净利润为5069.00万元。
(二)金华南方基本情况
1、名称:金华南方水泥有限公司
2、企业性质:有限责任公司
3、注册地:浙江省金华市中山路365号12楼
4、主要办公地点:浙江省金华市中山路365号12楼
5、法定代表人:蒋晓萌
6、注册资本:人民币10亿元
7、经营范围:水泥及制品的生产(限子公司及分公司经营)、研发、销售、技术服务。
8、目前的股权结构:
|
股东名称 |
占注册资本的比例(%) |
|
南方水泥有限公司 |
100 |
9、金华南方最近一年的主要财务指标
经具有从事证券、期货业务资格的天职国际会计师事务所审计,截止2016年12月31日,金华南方的总资产为320247.96万元,所有者权益合计123779.31万元;2016年的营业总收入为0万元,净利润为13235.99万元。
三、交易标的基本情况
(一)交易标的
1、名称:杭州山亚南方水泥有限公司
2、企业性质:有限责任公司
3、注册地:杭州富阳区渌渚镇上港码头
4、主要办公地点:杭州富阳区渌渚镇上港码头
5、法定代表人:蒋晓萌
6、注册资本:人民币2亿元
7、成立时间:2002年6月27日
8、经营范围:水泥、水泥熟料、水泥机电设备制造,销售;水泥用石灰岩开采、销售(采矿许可证有效期至2020年10月9日)。
9、目前的股权结构:
|
股东名称 |
占注册资本的比例(%) |
|
浙江金华南方尖峰水泥有限公司 |
100 |
10、山亚南方最近一年又一期的主要财务指标
经具有从事证券、期货业务资格的天职国际会计师事务所审计(天职业字[2017]11774号),截止2016年12月31日,山亚南方的总资产为62415.63万元,所有者权益合计30552.08万元;2016年的营业收入为40393.23万元,净利润为4293.19万元。截止2017年6月30日,山亚南方的总资产为63365.53万元,所有者权益合计28022.76万元;2017年上半年的营业收入为23180.62万元,净利润为1432.58万元。2017年半年度的财务报表未经审计。
11、山亚南方为南方尖峰全资子公司,最近12月无资产评估、增资、减资或改制情况。标的股权的产权清晰,不存在抵押、质押及其他任何限制转让的情况,不涉及诉讼、仲裁事项或查封、冻结等司法措施以及妨碍权属转移的其他情况。
12、山亚南方拥有一条日产5000吨熟料新型干法水泥生产线,目前正常生产,运行良好。
(二)关联交易价格的确定
本次股权转让的交易价以具有证券从业资格的天职国际会计师事务所审计(天职业字[2017]9406号)审计报告所载的南方尖峰对山亚南方的长期股权投资账面价值177,427,900.00元人民币(大写:壹亿柒仟柒佰肆拾贰万柒仟玖佰元整)为准,按尖峰水泥和金华南方所占南方尖峰的股权比例计算。尖峰水泥应付股权转让款为62,099,765.00元,金华南方应付股权转让款115,328,135.00元。
四、关联交易的主要内容和履约安排
(一)交易双方
出让方(甲方):南方尖峰
受让方(乙方):尖峰水泥、金华南方
(二)交易内容
甲方同意将所持山亚南方的100%股权转让给乙方,乙方同意根据约定受让山亚南方的100%股权(其中:尖峰水泥受让35%股权,金华南方受让65%股权)。
(三)转让价格
甲、乙双方经协商后同意,本次标的股权转让的作价方式为固定价格,本次标的股权转让的价格为177,427,900.00元人民币(大写:壹亿柒仟柒佰肆拾贰万柒仟玖佰元整),由尖峰水泥与金华南方根据受让股权比例支付相应的股权转让款,即尖峰水泥支付股权转让款62,099,765.00元,金华南方支付股权转让款115,328,135.00元。
(四)支付方式和期限
甲、乙双方同意,在本次股权转让完成工商变更登记并甲方完成减资后十五个工作日内,乙方以货币方式向甲方支付股权转让价款。
(五)过户等其他安排
1、甲、乙双方应共同协助山亚南方在工商行政管理机关办理标的股权过户、新章程备案等登记事项的变更手续。与本次股权转让相关的税费由金华南方支付。
2、股权转让后,山亚南方的董事会由3名董事组成,其中受让方金华南方推荐2名董事,受让方尖峰水泥推荐1名。
3、受让方金华南方确认本次股权转让符合特殊税务处理(属于税务豁免)事项;若山亚南方、南方尖峰因本次股权转让而产生税费,导致尖峰水泥的股东权益受损,金华南方应向尖峰水泥进行全额补偿。
五、该关联交易的目的以及对上市公司的影响
本公司持有南方尖峰35%的股权,是本公司一项长期股权投资,公司一直按照权益法进行核算。本次股权重组后山亚南方的管理层级上移,以实现压减企业层级、提高运营效率的目的;受让双方按相同的计价依据、以各自所占南方尖峰的股权比例来确定本次受让山亚南方的股权转让比例和金额。
在股权重组完成后,南方尖峰不再持有山亚南方的股权,由本公司的控股子公司尖峰水泥直接持有山亚南方35%的股权,转让前后本公司的整体权益不变,本次关联交易对本公司财务状况和经营成果不会产生重大的影响。
六、该关联交易应当履行的审议程序
根据中国证监会《关于在上市公司建立独立董事制度的指导意见》、公司《章程》的有关规定,公司已在董事会审议该交易前,向公司独立董事报告了本次股权重组的关联交易事宜,公司独立董事认为:该项关联交易实质是为了压减企业层级、提高运营效率。该关联交易事项的相关资料齐全,关联交易价格以具有证券从业资格的天职国际会计师事务所审计(天职业字[2017]9406号)审计报告所载的南方尖峰对山亚南方的长期股权投资账面价值为依据,按尖峰水泥和金华南方各自所占南方尖峰的股权比例计算交易金额,交易的价格公平、合理。交易完成后,受让方的整体权益不变。
以上关联交易没有损害公司及股东的利益,同意将上述议案提交给公司第九届董事会第14次会议审议。
2017年8月2日,本公司召开了九届14次董事会,公司全体九名董事亲自参加了会议,关联董事蒋晓萌先生回避了该议案的表决,符合《公司法》和公司《章程》的有关规定,所做决议合法有效。经审议与表决,董事会以8票同意、0票反对、0票弃权审议通过了《关于山亚南方股权重组的关联交易议案》。
公司独立董事对该项决议发表了独立意见,认为:(1)本次关联交易价格公平、合理,不存在损害公司及股东利益的情况。有利于优化公司长期股权投资的股权结构,缩减持股层级,提高企业运营效率。(2)本次关联交易金额为62,099,765元,未超过公司最近一期经审计净资产绝对值的5%,需提交公司董事会审议,无需提交股东大会审议。该议案经公司第九届董事会第14次会议审议通过,关联董事蒋晓萌回避了表决,审议和表决程序合法有效,符合《公司章程》及其他法律、法规和规范性文件的要求。
董事会审计委员会对该事项发表了审核意见:认为(1)本次关联交易事项的相关资料齐全,公司管理层已与我们进行了全面的沟通。股权交易的价格公平、合理,交易遵循了公开、公正的原则。(2)本次关联交易股权转让实质是为了压减企业层级、提高运营效率而实施的股权重组,尖峰水泥和金华南方向子公司南方尖峰受让其所持的股权,受让双方按相同的计价依据、以所占南方尖峰的股权比例确定股权转让金额。重组完成后,受让方的整体权益不变。(3)本次关联交易严格按照有关法律程序进行,符合相关法律法规及《公司章程》的有关规定,不存在损害公司或股东利益的情形。本委员会同意本次关联交易事项。
七、上网公告附件
(一)独立董事事前认可声明
(二)独立董事的独立意见
(三)董事会审计委员会对关联交易的书面审核意见
(四)财务报表和审计报告
特此公告
浙江尖峰集团股份有限公司
董事会
二〇一七年八月二日
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11